Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Abstract: A method includes forming a plurality of pockets of semiconductor material in a semiconductor substrate. The plurality of pockets are electrically isolated from the semiconductor substrate. The method further involves forming a metal-oxide-semiconductor field-effect transistor (MOSFET) in a pocket of the plurality of pockets, the MOSFET being a vertical trench shielded gate MOSFET. The method further includes forming an electrical connection to a drain region of the MOSFET vertically below a trench and a mesa of the MOSFET.

Abstract: The present disclosure relates to inhibitors of phosphodiesterase 1 (PDE1) useful for the engagement with the central nervous system. The disclosure further relates to the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment of a condition, disease or disorder associated with the dopamine D1 receptor intracellular pathway, e.g., a condition, disease or disorder characterized by a deficit in attention, cognition, memory and/or inhibitory processing.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

Abstract: A method, system, apparatus, and/or device to align a miniaturized impedance sensor over the muscular-walled tube of a user. The method, system, apparatus, and/or device may include: a band comprising a shape, size, and flexibility designed for attaching the band to a body part of a user, where the body part includes a dermal layer and a muscular-walled tube; a miniaturized impedance sensor embedded in the band and positioned in the band to be pressed against a portion of the body part adjacent to the muscular-walled tube as the user wears the band, where the miniaturized impedance sensor may include two or more miniaturized electrode strips or an array of miniaturized electrode pillars; and an alignment device embedded in the band and configured in the band to align the miniaturized impedance sensor over the muscular-walled tube as the user wears the band.

Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: A washing toilet seat assembly includes a toilet seat and a housing configured to be coupled to a toilet bowl to support the toilet seat about a pivot axis. The housing includes a cartridge interface and a cover moveable between an open position allowing access to the cartridge interface and a closed position blocking access to the cartridge interface. The washing toilet seat assembly further includes a cartridge removably coupled to the cartridge interface, the cartridge including a dispensable solution, and a spray wand moveably supported by at least one of the toilet seat or the housing. The spray wand is in fluid communication with the cartridge to dispense the dispensable solution, and the spray want is configured to dispense the dispensable solution during operation of the washing toilet seat assembly as a user sits on the toilet seat.

Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

Abstract: An assembly for delivering an implantable medical device, the assembly includes an implantable medical device including an attachment feature and a delivery device that is adapted to releasably secure the implantable medical device, the delivery device including an attachment element adapted to create an interference fit with the attachment feature of the implantable medical device. The delivery device is adapted to enable a user to selectively disengage the interference fit between the attachment element of the delivery device and the attachment feature of the implantable medical device with a short linear motion when the delivery device is positioned proximate a delivery site for the implantable medical device.

Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-ol, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.

Abstract: A quick-release latch may include a male component and a female component. The male component may include an insertable male portion comprising a top wall, a bottom wall, and one or more sidewalls. The male component may also include a first strap attachment portion defining a first plurality of strap openings each having a laterally extending strap slot and a mouth positioned off-center of and providing exterior access to the respective strap slot. The female component may include a female receptacle portion comprising a top wall, a bottom wall, and one or more sidewalls collectively forming a receptacle configured to receive and releasably lock to the insertable male portion of the male component. The top wall of the female receptacle may include a cantilever wall partially surrounded by one or more slots. The cantilever wall may extend proximate a same plane as the top wall.

Abstract: A computing device includes a hardware switch that is activated when a primary Basic Input/Output System (BIOS) of a first BIOS chip of the device fails to load an Operating System (OS) image from an OS partition of a hard drive. The switch passes control to a backup BIOS that executes from a backup BIOS chip. The backup BIOS loads a recovery image from BIOS recovery partition of the hard drive, which causes a reflash application to execute from the recovery image. Reflash application obtains a recovery BIOS from the BIOS recovery partition of the hard drive, reflashes/writes the recovery BIOS onto the first BIOS chip and reboots the device. Following reboot of the device, recovery BIOS loads the OS image from the OS partition, and recovery BIOS becomes the primary BIOS on the first BIOS chip of the device.

Abstract: A method, system, apparatus, and/or device for measuring a physiological condition of a user. The method, system, apparatus, and/or device may include: a band configured to attach to a body part of a user; a housing coupled to the band; a processing device integrated into the band or disposed within the housing; an interface integrated into the band or disposed within the housing; and a miniaturized impedance sensor.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

Abstract: The invention relates to pharmaceutical compositions comprising, compounds of Formula Q: wherein W is —N(H)—, or —N(CH3)—, and Y is —C(?O)— or —O—, in free base or pharmaceutically acceptable salt form, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.